Gantenerumab

Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease.[1][2] A phase I clinical trial has been conducted in 2006/07.[3]

Gantenerumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetBeta-amyloid (Aβ40/42)
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6496H10072N1740O2024S42
Molar mass146.3 kg/mol (peptide) g·mol−1
 NY (what is this?)  (verify)

Gantenerumab is currently being evaluated in a prodromal Alzheimer's disease population in the Scarlet Road study, a global phase II study of approximately 360 subjects in 100 centers in 15 countries.[4]

One clinical study was stopped on December 19, 2014 after disappointing results.[5]

As of late 2014, Phase III clinical trials are ongoing.[6]

References
  1. Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab American Medical Association.
  2. International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
  3. Clinical trial number NCT00531804 for "A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease" at ClinicalTrials.gov
  4. http://www.scarletroadstudy.com/en-CA/index.aspx
  5. http://www.nasdaq.com/press-release/morphosyss-partner-roche-provides-update-on-trial-of-gantenerumab-in-prodromal-alzheimers-patients-20141219-00045
  6. H. Spreitzer (10 November 2014). "Neue Wirkstoffe – Gantenerumab". Österreichische Apothekerzeitung (in German) (23/2014): 55.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.